Eptinezumab (Vyepti) Desensitization Protocol

Posted on December 20 2025, By: Cerebral Torque

← Back to Migraine Resource Hub
Stay in the Loop on the Latest in Migraine:

Eptinezumab (Vyepti) Desensitization Protocol

A breakthrough approach for migraine patients with hypersensitivity reactions to CGRP therapy
Quick Navigation - Eptinezumab Desensitization
Introduction & Background Understanding Hypersensitivity Clinical Case Studies The 10-Step Protocol Proposed Mechanisms Pharmacovigilance Data Clinical Guidance Conclusions

Introduction: When a Working Treatment Causes Reactions

For patients with treatment-resistant chronic migraine, finding an effective preventive therapy can feel like striking gold. Eptinezumab, an intravenous anti-CGRP monoclonal antibody given quarterly, has been a game-changer for many who failed other preventive options. But what happens when the treatment that finally works starts causing allergic reactions?

Until now, patients facing hypersensitivity reactions to eptinezumab had essentially one option, to stop the medication. This was especially devastating for those who had already cycled through propranolol, topiramate, amitriptyline, flunarizine (outside the US), and other preventives without success.

A team at Nice University Hospital in France has published the first successful desensitization protocol for eptinezumab, offering hope for patients caught between effective migraine control and adverse reactions.

Why This Matters

Before this protocol was published, no desensitization approach for eptinezumab existed anywhere in the medical literature. The research team checked both the French national pharmacovigilance database and the WHO international pharmacovigilance database (VigiBase) and found no documented tolerance induction protocols. This truly is a first.

Hypersensitivity Reactions to Eptinezumab: What We Know

In the clinical trials, hypersensitivity reactions to eptinezumab were relatively uncommon but not rare. The numbers varied depending on the patient population studied.

0.7%
Pooled Trial Rate
15 of 2,076 patients in the original pooled clinical trial population
2-3%
Treatment-Resistant Population
Higher rates in the DELIVER trial involving patients who failed 2-4 prior preventives
515
VigiBase Reports
Potential immunoallergic reactions documented in the WHO pharmacovigilance database

Reported reactions have included urticaria (hives), flushing, rash, pruritus (itching), and in rare cases, anaphylaxis. The important thing to understand is that these reactions were documented in trials without detailed investigation into their underlying mechanisms.

Types of Drug Hypersensitivity Reactions

Drug hypersensitivity reactions fall into four major categories based on immunologic mechanism. Type I reactions are immediate and IgE-mediated (classic allergic reactions). Type II involves cytotoxic IgG-mediated responses. Type III involves immune complex disease. Type IV reactions are delayed and cell-mediated. Only Type I and Type IV reactions can be evaluated through skin testing, which makes determining the exact mechanism challenging in many cases.

Clinical Case Studies: Two Success Stories

The Nice University Hospital team documented two patients who successfully underwent their desensitization protocol. Both had chronic migraine refractory to multiple preventive therapies and both experienced significant reactions to eptinezumab, but the medication had been effective for their migraine control.

1
36-Year-Old Nurse with Treatment-Resistant Migraine
Prior Failed Therapies
Propranolol, amitriptyline, topiramate, flunarizine
Response to Eptinezumab
75% reduction in migraine days
Allergic History
None

What happened: Her first eptinezumab infusion (100 mg IV over 30 minutes) went fine. After the second dose, she developed a pruritic erythematous rash on both forearms about 2.5 hours post-infusion. It resolved within 48 hours with cetirizine. For her third dose, she was premedicated with cetirizine 10 mg, but a more extensive rash appeared 45 minutes post-infusion.

Skin testing: Intradermal tests performed 8 months after the initial dose were negative for eptinezumab at concentrations ranging from 10-3 to 10-1 with a pure 100 mg/mL solution.

Outcome: Desensitization was successful. Though delayed localized erythema with moderate pruritus appeared within 72 hours of the first desensitization, it resolved within 48 hours with cetirizine. Subsequent desensitizations at 3-month intervals were progressively better tolerated, with no further reactions since the third desensitization.

2
26-Year-Old Student with Multiple Comorbidities
Prior Failed Therapies
Propranolol, amitriptyline, topiramate, pizotifen, flunarizine, onabotulinumtoxinA, occipital nerve block
Comorbidities
Moderate asthma, anxiety, depression, renal lithiasis
Daily Medications
Montelukast, formoterol/budesonide, duloxetine

What happened: Her very first eptinezumab infusion triggered generalized urticaria with immediate bronchospasm requiring oxygen, dexchlorpheniramine 4 mg, and salbutamol. Because the medication was effective for her migraines, a second attempt 3 months later with premedication (cetirizine 10 mg and IV methylprednisolone 1 mg/kg) resulted in generalized urticaria 30 minutes post-infusion, though without systemic involvement.

Skin testing: Intradermal eptinezumab skin tests were negative using the same dilutions as Case 1.

Outcome: Desensitization using the 10-step protocol was successful with no adverse events. No adverse events occurred for the next three desensitization courses, allowing the protocol to be accelerated after the third administration.

The 10-Step Desensitization Protocol

The protocol developed at Nice University Hospital follows European safety recommendations for drug desensitization. It was designed to gradually introduce the medication while minimizing the risk of severe reactions.

Safety Requirements
Emergency Equipment Emergency trolley on standby
Staff Training Personnel trained in resuscitation
Intensive Care ICU facilities nearby
Monitoring Vital signs before each step
Dose Escalation Maximum doubling between steps
Time Between Steps 20-30 minutes

Premedication Protocol

30 minutes before starting: dexchlorpheniramine 5 mg plus methylprednisolone 60 mg

Eptinezumab Desensitization Protocol

This 10-step protocol gradually increases the dose from 0.1 mg to a cumulative dose of 99 mg over approximately 4 hours and 40 minutes. After three well-tolerated administrations, the protocol can be accelerated (shown in parentheses).

Step Concentration (mg/mL) Duration (min) Infusion Rate (mL/h) Volume (mL) Dose (mg) Cumulative (mg)
1 0.10 20 (15) 3 (4) 1 0.1 0.1
2 0.10 20 (15) 6 (8) 2 0.2 0.3
3 0.10 20 (15) 12 (16) 4 0.4 0.7
4 0.10 20 (15) 24 (32) 8 0.8 1.5
5 1.00 20 (15) 5 (6) 1.5 1.5 3
6 1.00 20 (15) 9 (12) 3 3 6
7 1.00 20 (15) 18 (24) 6 6 12
8 1.00 20 (15) 36 (48) 12 12 24
9 10.0 60 (40) 3 (4) 2.5 25 49
10 10.0 60 (40) 5 (8) 5 50 99
Total - 4h 40m (3h 30m) - - - 99 mg

Protocol Acceleration

After three well-tolerated desensitization administrations, the protocol can be accelerated by reducing administration time and increasing the dose of several steps. The accelerated timing reduces total infusion time from 4 hours 40 minutes to approximately 3 hours 30 minutes.

What's Actually Causing These Reactions?

One of the most interesting findings from these cases is that the skin tests were negative for both patients, suggesting the reactions were not classic IgE-mediated allergic responses. So what's going on?

Proposed Mechanisms
Complement Activation

As a humanized monoclonal antibody, eptinezumab has a modified Fc region designed to minimize complement activation. However, complement activation via anaphylatoxins (C3a/C5a) remains possible when soluble immune complexes form. These reactions may respond well to desensitization.

Polysorbate 80 Reactions

Polysorbate 80 is an excipient in eptinezumab known to trigger pseudoallergic reactions with other monoclonal antibodies. High doses can activate basophils nonspecifically, causing hypersensitivity reactions. If this is the mechanism, slowing down the infusion rate can help achieve tolerance.

Interleukin/Cytokine Reactions

Similar to what's seen with rituximab, some patients may experience cytokine release reactions. These are sensitive to infusion speed, which is why slower initial administration is the foundation of the desensitization protocol.

Clinical Recommendation

The research team suggests measuring complement levels and interleukin-6 (IL-6) when hypersensitivity reactions occur during infusion. If these levels are abnormal, patients would likely benefit from a slower infusion rate. Understanding the mechanism directly affects premedication strategy, monitoring requirements, and desensitization design.

What the Global Data Shows

The researchers analyzed data from VigiBase, the WHO international pharmacovigilance database managed by the Uppsala Monitoring Centre. This database collects spontaneous adverse event reports from 172 member countries.

515
Total Reports
Potential immunoallergic reactions to eptinezumab documented in VigiBase
185
Hypersensitivity Cases
Versus 70 expected, indicating a disproportionality signal
60
Infusion-Related Reactions
Versus 10 expected, showing a strong signal

Among the six French cases in the database, all reactions occurred after the first administration, featuring early-onset cutaneous or respiratory symptoms consistent with the infusion-related reactions reported in clinical trials.

The NSAID Connection

Some patients in the VigiBase reports were concurrently taking NSAIDs, which are known cofactors for anaphylaxis. For migraine patients who frequently use NSAIDs, this may lower the threshold for mast cell activation or increase mucosal permeability. This should be considered when interpreting reactions, though notably neither of the two successfully desensitized patients was taking NSAIDs during their reactions.

Clinical Guidance for Healthcare Providers

Based on these findings, the research team offers several recommendations for managing patients who experience hypersensitivity reactions to eptinezumab.

When to Consider Desensitization
Patient Response Eptinezumab is effective for their migraine
Treatment History Failed multiple other preventive therapies
Reaction Severity Mild to moderate hypersensitivity
Premedication Trial Failed to prevent reactions

Before Proceeding to Desensitization

  • Try premedication first: Antihistamines with or without corticosteroids may be sufficient for some patients
  • Perform skin testing: Even though results may be negative, this helps characterize the reaction
  • Consider slowing the infusion: Many reactions are rate-dependent and may resolve with slower administration
  • Measure biomarkers during reactions: Tryptase, complement levels, and IL-6 can help determine the mechanism
Distinguishing Infusion-Related Reactions from True Allergy

Infusion-related reactions typically appear from the first exposure, and hypersensitivity markers like tryptase are negative. For these, the recommendation is to first slow down the infusion and try administration under antihistamine to reduce nonspecific histamine release before proceeding with full desensitization.

True IgE-mediated reactions would show positive skin testing and elevated tryptase (120% increase from baseline). These require the full desensitization protocol approach.

Conclusions: A New Option for Treatment-Resistant Patients

These two cases demonstrate that mild to moderate recurrent hypersensitivity reactions to eptinezumab can be successfully managed through hospital-based desensitization when premedication alone fails.

Key Takeaways
Feasibility Protocol is safe and effective
Skin Testing Both patients had negative results
Mechanism Likely non-IgE mediated
Improvement Tolerance improved with successive treatments
Protocol Acceleration Possible after 3 well-tolerated sessions

The absence of severe clinical adverse effects and the therapeutic efficacy of eptinezumab justified this approach. The fact that tolerance improved with each successive desensitization is encouraging and suggests that the protocol may become easier to administer over time.

The authors note that the lack of standardized immunological biomarker assessment during reactions highlights the need for protocols that include complement and IL-6 testing. Understanding the underlying mechanism directly affects treatment decisions, from premedication strategy to monitoring requirements to desensitization design.

"These cases illustrate mild and moderate, but recurrent immediate hypersensitivity to eptinezumab, successfully managed via a first hospital-based desensitization after the failure of premedication alone. The absence of severe clinical adverse effects and the therapeutic efficacy of eptinezumab justified this approach, which proved to be both feasible and effective."
Important Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment. Desensitization protocols must be performed in hospital settings with appropriate emergency equipment and trained personnel. Always consult with a qualified healthcare provider, ideally one experienced in drug allergy and desensitization, before attempting any desensitization approach.

References

  1. Gerard B, Praudel H, Lanteri-Minet M, et al. First successful protocol for desensitization to eptinezumab. Headache. 2025;00:1-4. doi:10.1111/head.70000
  2. Smith TR, Spierings ELH, Cady R, et al. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021;22:16. doi:10.1186/S10194-021-01227-5
  3. Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21:597-607. doi:10.1016/S1474-4422(22)00185-5
  4. Wilkerson RG. Drug hypersensitivity reactions. Emerg Med Clin North Am. 2022;40:39-55. doi:10.1016/J.EMC.2021.09.001
  5. Barbaud A, Garvey LH, Torres M, et al. EAACI/ENDA position paper on drug provocation testing. Allergy. 2024;79:565-579. doi:10.1111/ALL.15996
  6. Isabwe GAC, Garcia Neuer M, de las Vecillas Sanchez L, Lynch DM, Marquis K, Castells M. Hypersensitivity reactions to therapeutic monoclonal antibodies: phenotypes and endotypes. J Allergy Clin Immunol. 2018;142:159-170.e2. doi:10.1016/j.jaci.2018.02.018
  7. Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95:593-599. doi:10.1016/S1081-1206(10)61024-1
  8. Pichler WJ. Immune pathomechanism and classification of drug hypersensitivity. Allergy. 2019;74:1457-1471. doi:10.1111/ALL.13765
  9. Moore JE, Bloom PC, Chu CC, et al. Rituximab induced cytokine release with high serum IP-10 (CXCL10) concentrations is associated with infusion reactions. Leuk Res. 2023;129:107072. doi:10.1016/j.leukres.2023.107072
  10. Muñoz-Cano R, Pascal M, Araujo G, et al. Mechanisms, cofactors, and augmenting factors involved in anaphylaxis. Front Immunol. 2017;8:1193. doi:10.3389/FIMMU.2017.01193

MigraineScience Blog

Join Our Community